Manchester Adult Cystic Fibrosis Centre, University Hospitals South Manchester NHS Foundation Trust, Southmoor Rd, Manchester, M23 9LT, England.
Chest. 2010 Jun;137(6):1405-9. doi: 10.1378/chest.09-2406. Epub 2010 Jan 15.
Although there is now compelling evidence for cross-infection by strains of Pseudomonas aeruginosa at some specialist (cystic fibrosis [CF]) centers, the clinical impact of infection by transmissible strains is unclear.
In an 8-year prospective study, we compared the clinical outcome of two groups of patients with CF infected by transmissible (n = 28) and sporadic strains (n = 52) of P aeruginosa.
There were no differences between the two groups in survival, annual changes in spirometry, or BMI. There were differences in requirements for IV antibiotic treatment (mean [SD]: 29.3 [21.9] days vs 53.1 [32.5] days) and hospitalization (median [range]: 11.6 [1.1, 49.3] days vs 23.3 [5.5, 103.6] days) between patients infected with sporadic and transmissible strains of P aeruginosa, respectively.
We conclude that infection by transmissible P aeruginosa does not increase mortality but is associated with increased health-care and antibiotic use for patients with CF.
虽然现在有令人信服的证据表明，在某些专科中心（囊性纤维化[CF]）中，铜绿假单胞菌的菌株存在交叉感染，但可传播菌株感染的临床影响尚不清楚。
在一项为期 8 年的前瞻性研究中，我们比较了两组 CF 患者的临床结局，他们分别感染了可传播（n=28）和散发性（n=52）铜绿假单胞菌菌株。
两组在生存率、肺功能年度变化或 BMI 方面无差异。两组患者在 IV 抗生素治疗（平均[SD]：29.3[21.9]天 vs 53.1[32.5]天）和住院治疗（中位数[范围]：11.6[1.1，49.3]天 vs 23.3[5.5，103.6]天）方面存在差异。
我们得出结论，感染可传播的铜绿假单胞菌不会增加死亡率，但会导致 CF 患者的医疗保健和抗生素使用增加。
